Karyopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 03 2018 - 7:00AM
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage
pharmaceutical company, today announced that Michael Kauffman, MD,
PhD, Chief Executive Officer, will present at the 36th Annual J.P.
Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30
a.m. PT at the Westin St. Francis in San Francisco.
A live webcast of the event will be available on
the "Events & Presentations" page in the Investors section of
the Company's website at
http://investors.karyopharm.com/events.cfm. A replay of the
webcast will be archived on the Company's website for 90 days
following the presentation.
About Karyopharm
Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a
clinical-stage pharmaceutical company focused on the discovery and
development of novel first-in-class drugs directed against nuclear
transport and related targets for the treatment of cancer and other
major diseases. Karyopharm's SINE™ compounds function by binding
with and inhibiting the nuclear export protein XPO1 (or
CRM1). The Company's initial focus is on seeking regulatory
approval and commercialization of its lead drug candidate, oral
selinexor (KPT-330). To date, over 2,200 patients have been
treated with selinexor and it is currently being evaluated in
several mid- and later-phase clinical trials across multiple cancer
indications, including in multiple myeloma in a pivotal, randomized
Phase 3 study in combination with Velcade® (bortezomib) and
low-dose dexamethasone (BOSTON) and in combination with low-dose
dexamethasone (STORM) and backbone therapies (STOMP), and in
diffuse large B-cell lymphoma (SADAL) and liposarcoma (SEAL), among
others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing
or currently planned, including multiple studies in combination
with one or more approved therapies in a variety of tumor types to
further inform the Company's clinical development priorities for
selinexor. In addition to single-agent and combination
activity against a variety of human cancers, SINE™ compounds have
also shown biological activity in models of neurodegeneration,
inflammation, autoimmune disease, certain viruses and
wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham,
currently has five investigational programs in clinical or
preclinical development. For more information, please visit
www.karyopharm.com.
Velcade® is a registered trademark of Takeda
Pharmaceutical Company Limited
Contacts:
Investors:Kimberly Minarovich(646)
368-8014kimberly@argotpartners.com
Gus Jenkins(646) 351-0167
gus@argotpartners.com
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Sep 2023 to Sep 2024